NurExone Biologic
TSXV:NRXHaifa, Israel· Est.
Exosome‑powered regenerative therapies for CNS injuries, leveraging a scalable nanodrug platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Exosome‑powered regenerative therapies for CNS injuries, leveraging a scalable nanodrug platform.
Central Nervous SystemOphthalmology
Technology Platform
ExoTherapy – a proprietary exosome production and loading system that creates nanodrugs capable of crossing biological barriers and delivering therapeutic payloads to damaged tissue.
Opportunities
Licensing the ExoTherapy platform to third‑party developers and achieving first‑in‑human data for ExoPTEN could unlock multi‑billion‑dollar market potential across CNS and ophthalmic indications.
Risk Factors
Clinical translation of exosome therapeutics remains uncertain, and scaling GMP manufacturing while maintaining batch consistency poses technical and regulatory challenges.
Competitive Landscape
NurExone competes with other exosome‑focused firms such as Codiak, Aeglea, and Exosome Diagnostics, but differentiates through its proprietary loading technology, intranasal delivery route, and early focus on acute CNS injuries.